Skip to main content
# Title Research Year
121 METRONOMIC CAPECITABINE WITH VINORELBINE AS A SECOND LINE CHEMOTHERAPY IN ADVANCED BREAST CANCER 2015
122 Rate of thyroglossal duct remnant visualization
after total thyroidectomy for differentiated thyroid
carcinoma and its impact on clinical outcome of
radioactive iodine (I‑131) ablation
2015
123 Concurrent Radiochemotherapy in Locally Advanced Head and Neck Cancer: Analysis of Treatment Results and Prognostic factors 2015
124 NAVELBLINE AND CAPECITABINE (NAVCAP) FOLLOWED EITHER BY NAVCAP OR BY WEEKLY DOCETAXEL IN THE FIRST-LINE TREATMENT OF HER-2/NEU NEGATIVE METASTATIC BREAST CANCER. 2015
125 GDP versus DHAP in relapsed and refractory Hodgkin disease 2015
126 Concurrent Radiochemotherapy in Locally Advanced Head and Neck Cancer: Analysis of Treatment Results and Prognostic factors 2015
127 NAVELBLINE AND CAPECITABINE (NAVCAP) FOLLOWED EITHER BY NAVCAP OR BY WEEKLY DOCETAXEL IN THE FIRST-LINE TREATMENT OF HER-2/NEU NEGATIVE METASTATIC BREAST CANCER. 2015
128 GDP versus DHAP in relapsed and refractory Hodgkin disease 2015
129 GDP versus DHAP in relapsed and refractory Hodgkin disease 2015
130 Which is More Effective; Docetaxel, Doxorubicin
and Cyclophosphamide Or 5-Fluorouracil,
Doxorubicin and Cyclophosphamide in Adjuvant
Treatment of Early Stage Node Positive Breast
Cancer?
2015